Fast and Secure Delivery Worldwide Express & Expedited Shipping Service
USD $52.95
Lifanta 5% Ophthalmic Solution 3ml Multi-dose vial provides relief for dry eyes. With Lifitegrast 5%, it helps reduce inflammation and improve eye comfort. Ideal for those needing consistent eye care.
IndiaLifanta Ophthalmic Solution contains lifitegrast 5% w/v, a prescription ophthalmic medicine used in the management of dry eye disease (DED). Lifitegrast works differently from ordinary lubricating eye drops because it targets an inflammatory pathway associated with chronic dry eye.
Lifanta contains the same active ingredient and strength as Xiidra® — lifitegrast 5% (50 mg/mL). However, Lifanta and Xiidra are different brands and should not be considered identical products. Packaging, inactive ingredients, approved indications and regulatory status may vary by country.
Prescription medicine: Use Lifanta only as directed by your doctor, ophthalmologist, optometrist or pharmacist. Do not switch from Xiidra or another prescription dry-eye treatment without professional advice.
Lifanta is used for the treatment of dry eye disease, particularly when inflammation of the ocular surface contributes to ongoing symptoms.
Dry eye disease is not simply a lack of tears. In many people it involves a combination of tear-film instability, rapid evaporation, reduced tear production and inflammation. You can learn more in our guide to severe dry-eye relief and treatment options.
Dry-eye symptoms may include:
Lifitegrast belongs to a class of medicines known as lymphocyte function-associated antigen-1 (LFA-1) antagonists.
Inflammation can contribute to the cycle of dry eye disease. Lifitegrast binds to LFA-1 and blocks its interaction with ICAM-1 (intercellular adhesion molecule-1). This interaction is associated with immune-cell activity and inflammatory signaling on the ocular surface.
By interfering with this pathway, lifitegrast helps address an important inflammatory component of dry eye disease rather than merely coating or lubricating the surface of the eye.
| Feature | Lifanta | Xiidra® |
|---|---|---|
| Active Ingredient | Lifitegrast | Lifitegrast |
| Strength | 5% w/v | 5% / 50 mg/mL |
| Drug Class | LFA-1 antagonist | LFA-1 antagonist |
| Primary Use | Dry eye disease | Signs and symptoms of dry eye disease |
| Route | Ophthalmic | Ophthalmic |
| Brand | Lifanta | Xiidra® |
Key point: Lifanta contains the same active drug, lifitegrast 5%, as Xiidra. It should therefore be described as containing the same active ingredient and strength as Xiidra rather than simply stating that Lifanta “is Xiidra.”
For appropriately selected patients, lifitegrast offers a different approach from conventional artificial tears because it targets the inflammatory component of dry eye disease.
Lifitegrast is not intended to work like an instant lubricating eye drop. Prescription anti-inflammatory dry-eye treatments may need continued use before their full benefit becomes apparent.
In clinical studies of Xiidra, improvement in eye-dryness symptoms was observed as early as approximately 2 weeks in some studies and some patients, while improvements were also demonstrated at 6 and 12 weeks.
Individual response varies. Continue using your prescribed treatment according to your healthcare professional's directions unless you are advised to stop.
Always follow the directions supplied with Lifanta and the instructions given by your prescribing healthcare professional.
The commonly recommended regimen for lifitegrast ophthalmic solution 5% is:
Instill one drop into each affected eye twice daily, approximately 12 hours apart.
Contact lenses should generally be removed before administering lifitegrast.
For Xiidra, contact lenses may be reinserted 15 minutes after administration. Follow the instructions provided specifically with Lifanta and any advice given by your eye-care professional.
Lifanta and ordinary lubricating eye drops serve different purposes.
Artificial tears primarily lubricate and supplement the tear film, often providing temporary relief from dryness and irritation.
Lifitegrast is a prescription medication that targets an inflammatory pathway associated with dry eye disease.
Patients with evaporative dry eye may also benefit from lipid-focused lubrication depending on the underlying cause. Read our complete guide to evaporative dry eye disease.
Lifanta and Restasis are both prescription treatments used in dry-eye management, but they contain different medicines and work through different mechanisms.
Lifanta: contains lifitegrast 5%, an LFA-1 antagonist.
Restasis: contains cyclosporine ophthalmic emulsion, an immunomodulatory medicine used in chronic dry-eye management.
Patients researching alternative prescription approaches can view Restasis eye drops for dry eyes or see the Restasis 0.5MG 30s product page.
Neither treatment should automatically be considered better. Your eye-care professional may consider your type of dry eye, severity, tear production, ocular inflammation, previous treatments, medical history and tolerability before recommending therapy.
Meibomian gland dysfunction (MGD) is an important cause of evaporative dry eye. The meibomian glands produce oils that help slow evaporation of the tear film.
When these glands become blocked or produce poor-quality oil, tears may evaporate too rapidly and the ocular surface can become irritated and inflamed.
Lifitegrast may be used when an eye-care professional identifies inflammatory dry-eye disease, but it does not directly unblock the meibomian glands.
For more information, read our guide to NovaTears and meibomian gland dysfunction.
Lifanta and NovaTears address dry eye in very different ways.
Lifanta (lifitegrast) targets an inflammatory pathway associated with dry eye disease, while NovaTears contains perfluorohexyloctane and is designed to reduce tear evaporation.
Patients with evaporative dry eye or MGD can also explore NovaTears Preservative-Free Lubricating Eye Drops 3mL.
These products are not interchangeable, and some patients may have mixed dry-eye disease requiring more than one therapeutic approach under professional guidance.
Like all prescription medicines, lifitegrast may cause side effects.
Commonly reported adverse effects associated with lifitegrast ophthalmic solution include:
Contact your doctor or pharmacist if an adverse effect becomes severe, persistent or concerning.
Do not use Lifanta if you have a known hypersensitivity to lifitegrast or any other ingredient in the formulation.
Seek urgent medical attention if you develop symptoms such as severe swelling of the eyes, face, lips, tongue or throat, difficulty breathing, difficulty swallowing, wheezing or another rapidly worsening allergic reaction.
Tell your healthcare professional before treatment if you:
Available human data regarding ophthalmic lifitegrast during pregnancy are limited. If you are pregnant, planning pregnancy or breastfeeding, discuss the potential benefits and risks with your doctor before starting treatment.
Some patients with chronic dry eye use more than one ophthalmic treatment. Your eye-care professional may recommend prescription therapy together with lubricating eye drops, eyelid care or another treatment depending on the cause of your dry eye.
If you use multiple ophthalmic medicines, ask your doctor or pharmacist how much time should be left between different eye drops.
Dry eye can have several causes, so identifying whether you have aqueous-deficient, evaporative or mixed dry eye can help guide appropriate treatment.
If Lifanta has been prescribed for your dry eye condition, select the required quantity and proceed with your order. A valid prescription is required for prescription medicines and must be reviewed before dispensing.
Need help with your prescription or order? Waldrugmart's pharmacy support team can assist with prescription submission, product questions and the ordering process.
Lifanta and Xiidra are different brands containing the same active ingredient, lifitegrast 5%. They should not be described as identical products because formulation details, packaging and regulatory approvals may differ.
Lifanta contains lifitegrast 5% w/v.
Lifanta is a prescription ophthalmic medicine used in the treatment of dry eye disease. Lifitegrast targets an inflammatory pathway involved in dry eye.
No. Lifitegrast is not a corticosteroid. It is an LFA-1 antagonist.
Yes. Both contain lifitegrast 5% as the active ingredient. Patients should nevertheless consult their healthcare professional before changing prescription brands.
Lifitegrast 5% is commonly administered as one drop in each eye twice daily, approximately 12 hours apart. Follow the specific directions supplied with Lifanta and your prescription.
Some patients in clinical studies of Xiidra experienced improvement in eye-dryness symptoms as early as approximately two weeks, while others required longer treatment. Response varies between patients.
Contact lenses should generally be removed before lifitegrast administration. Xiidra prescribing information allows lenses to be reinserted after 15 minutes. Follow the instructions provided specifically with Lifanta.
No. Lifanta contains lifitegrast, a prescription LFA-1 antagonist. Artificial tears primarily lubricate the ocular surface and work differently.
Lifanta contains lifitegrast, while Restasis contains cyclosporine. Both may be used in dry-eye management but have different mechanisms of action. Your healthcare professional can determine which treatment is appropriate for you.
Lifitegrast may help address ocular-surface inflammation associated with dry eye, but it does not directly open blocked meibomian glands. Patients with MGD may require additional treatments such as eyelid hygiene, warm compresses or other therapies recommended by an eye-care professional.
This product information is intended for educational purposes and does not replace medical advice, diagnosis or treatment from a qualified healthcare professional.
Prescription medicines should be used only as directed. Do not start, stop, change the dose of or substitute a prescribed ophthalmic medicine without consulting your doctor, ophthalmologist, optometrist or pharmacist.
Seek prompt medical attention for sudden changes in vision, severe eye pain, significant swelling, signs of infection or symptoms of a serious allergic reaction.
